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 Abstract 
In addition to mutations in ITG2B or ITGB3 genes causing defective αIIbβ3 
expression/function in Glanzmann’s thrombasthenia patients, platelet dysfunction can be 
due to genetic variability in proteins mediating inside-out activation of αIIbβ3. The RASGRP2 
gene is strongly expressed in platelets and neutrophils, where its encoded protein CalDAG-
GEFI facilitates the activation of Rap1 and subsequent activation of integrins. We used next-
generation (NGS) and whole exome sequencing (WES) to identify two novel function-
disrupting mutations in RASGRP2 accounting for the bleeding diathesis and platelet 
dysfunction in two unrelated families. Using a panel of 71 genes, we identified a 
homozygous change (c.1142C>T) in exon 10 of RASGRP2 in a 9-year old child of Chinese 
origin (Family 1). This variant led to a p.Ser381Phe substitution in the CDC25 catalytic 
domain of CalDAG-GEFI. In two Spanish siblings from Family 2, WES identified a nonsense 
homozygous variation (c.337C>T) (p.Arg113X) in exon 5 of RASGRP2. CalDAG-GEFI 
expression was markedly reduced in platelets from all patients and, using a novel in vitro 
assay, the nucleotide exchange activity was found to be dramatically reduced in CalDAG-
GEFI p.Ser381Phe. Platelets from homozygous patients exhibited agonist-specific defects in 
αIIbβ3 integrin activation and aggregation. In contrast, α- and δ-granule secretion, platelet 
spreading and clot retraction were not markedly affected. Integrin activation in the patients’ 
neutrophils was also impaired. These patients are the first cases of a CalDAG-GEFI deficiency 
due to homozygous RASGRP2 mutations that are linked to defects in both leukocyte and 
platelet integrin activation. 
 
Key points: 
• Novel function-disrupting mutations in CalDAG-GEFI, p.Ser381Phe and p.Arg113X, 
were identified in two unrelated families of different ethnic origin.  
• Homozygous carriers of these mutations displayed a moderate bleeding diathesis and 
an impairment/delay in the platelet aggregation response to most agonists. 
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Introduction 
One of the most severe inherited platelet disorders1,2 (IPDs) is Glanzmann’s thrombasthenia 
(GT),  which is caused by recessive mutations in either ITG2B or ITGB3 leading to defects in 
αIIbβ3 integrin activation and/or expression, and, consequently, severely impaired platelet 
aggregation in response to all platelet agonists3,4. Impaired platelet aggregation and 
bleeding can also be caused by mutations in genes for signaling proteins critical in the inside-
out activation of αIIbβ3. RASGRP2 was recently identified as one such gene affected in 
patients with a platelet function defect and a bleeding complication5. RASGRP2 codes for the 
protein CalDAG-GEFI, a guanine nucleotide exchange factor for the small GTPase Rap1. In 
platelets, Rap1 activity is regulated by two independent yet synergistic signaling pathways6. 
A fast but reversible activation pathway mediated by an increase in the intracellular calcium 
ion concentration and the activation of CalDAG-GEFI. And a slow but sustained pathway that 
requires signaling by protein kinase C and the ADP receptor, P2Y12, the target of anti-platelet 
drugs such as clopidogrel. While CalDAG-GEFI mediates GTP loading, i.e. the activation of 
Rap1, signaling by P2Y12 leads to the inhibition of Rasa3, a GTPase-activating protein critical 
in the inactivation of Rap17. In mice, genetic deletion of Rasgrp2 did not affect embryonic 
development and survival. Adult mice lacking CalDAG-GEFI showed marked protection from 
experimental thrombosis and a significant impairment in hemostasis8,9. Furthermore, these 
mice exhibited a mild defect in the adhesive function of neutrophils, another cell type that 
expresses significant levels of CalDAG-GEFI10. The studies by Canault et al.5 provided the first 
genetic evidence that (1) CalDAG-GEFI is also a critical regulator of integrin-mediated 
adhesion in human platelets, and (2) the molecular machinery controlling Rap1 activity in 
human platelets closely resembles that of murine platelets. No defects in neutrophil 
adhesion mediated by integrins were observed.   
In this study, we report two pedigrees characterized by a bleeding tendency and a platelet 
dysfunction due to impaired αIIbβ3 integrin activation.  Neutrophils from homozygous 
patients also showed a defect in β2-integrin activation in vitro, but no relevant infections 
were reported. These cases carry novel mutations in RASGRP2, a nonsynonymous change 
c.1142C>T in Family 1 and a nonsense change c.337C>T in Family 2. Both mutations led to a 
marked reduction in CalDAG-GEFI expression. Thus, these patients are the first cases of 
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a CalDAG-GEFI deficiency due to homozygous RASGRP2 mutations that are linked to defects 
in both leukocyte and platelet integrin activation. 
 
 
Methods 
 
Subjects, blood sampling and DNA collection 
The study involved three index cases from two unrelated families of Chinese (Family 1 ) and 
Spanish origin (Family 2). Venous blood was drawn from each patient and a parallel healthy 
control into 7.5% K3 EDTA tubes (for blood counts and DNA isolation), and into buffered 
0.105 M sodium citrate (for platelet and neutrophil function studies) using a 20-gauge 
needle. Samples were maintained at room temperature until processing.  Genomic DNA 
from EDTA blood samples was isolated using a DNeasy blood and tissue kit, following the 
manufacturer’s protocol (Qiagen, Hilden, Germany). DNA concentration was measured using 
a Qubit 2.0 fluorometer (Life Technologies, Carlsbad, CA). 
This investigation followed the Helsinki Declaration and had approval by the Ethics 
Committee of the Hospital Reina Sofía (Murcia, Spain). All subjects provided written 
informed consent.  
 
NGS gene panel  
A clinical NGS panel was designed (Design Studio, Illumina, San Diego, CA) with probes 
targeting all exons, 3´UTR and flanking regions, of each of the 71 genes depicted in 
Supplemental Table 1. The NGS was performed on a MiSeq Instrument, running MiSeq 
Control Software and according to a Nextera sequencing design (Illumina). This NGS panel 
was applied in the index case of Family 1.  In brief, fifty ng of the DNA was sequenced 
following Illumina’s standardized protocol. DNA libraries were normalized to 4 nM and 
pooled in equal volumes. We used the 300-cycle reagent kit. Specifically, the sample was 
sequenced using paired 150 nt reads, multiplexing twelve, dual indexed samples per run. 
Each run performed in this study contained twenty-four samples.  Minimum coverage per 
base was 100 reads. High sequence quality was based on Phred score of > 20, Quality > 20 
and Read coverage > 30 at each position within the reads. Sequence data was mapped to the 
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revised Cambridge Reference Sequence using the MiSeq’s integrated computer software 
platform (MiSeq Reporter, Illumina). 
 
Whole exome sequencing (WES)  
In two patients from Family 2 the sequencing of the whole exome was performed essentially 
as described11. Following enrichment of coding regions and intron/exon boundaries with the 
SureSelect human AllExon 50Mb kit (Agilent Technologies) captured libraries were 
sequenced on the Illumina HiSeq 2500 (Illumina) with 100 bp paired-end reads. 
Bioinformatic analysis was carried out as in previous studies11,12.  
 
Sanger sequencing  
Verification of the two mutations in the RASGRP2 gene that were identified in these patients 
by NGS and WES, and their segregation in the pedigrees was achieved by standard Sanger 
sequencing with specific primers, using an ABI 3730 automated sequencer. The following 
primer pairs were designed using the ExonPrimer script (http://ihg2.helmholtz-
muenchen.de/ihg/ExonPrimer.html):  
a) mutation C.1142 C>T  [p.Ser381Phe]  
RASGRP2 x 5F: GTCGACCTTTGGCCCTG  
RASGRP2 x 5R: AGTGCTCCGGCAAACTGG  
b) mutation C.337 C>T  [p.Arg113]  
RASGRP2 x 5F: ….. GGTGGTTGTCTCAAGGGTCT 
RASGRP2 x 5R: …. CGAGAGAGCAACATGACCCT 
Sequences in the PCR products were analysed using MutationSurveyor software available 
from SoftGenetics (http://www.softgenetics.com/mutationSurveyor.html). 
 
Platelet aggregation 
Platelet rich plasma (PRP) was obtained by centrifugation of citrated whole blood at 150 x g 
for 10 min. Platelet poor plasma (PPP) was prepared by a further centrifugation step of the 
same tube at 1000 x g for 20 min.  Light transmission aggregometry (LTA) was performed 
essentially as described3 using undiluted PRP in an Aggrecorder II aggregometer (Menarini 
Diagnostics, Florence, Italy).  Time course changes in the maximal percentage of light 
transmission of PRP over baseline (PPP) were recorded for 300s upon addition of various 
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platelet agonists (1.5 mM arachidonic acid, 25 µM Thrombin Receptor Activating Peptide 
(PAR1p), 2 and 10 µg mL-1 collagen, 10 µM ADP, or 100 nM phorbol 12-myristate 13-acetate 
(PMA).  
 
Platelet 14C-Serotonin release 
Platelet rich plasma was adjusted with homologous PPP to a the final platelet count to 250 x 
109L-1 and labelled with 1 µM 14C-serotonin (5-OH-14C-labelled tryptamine [14C-serotonin]; 
GE Healthcare, Barcelona, Spain) for 45 min at 37ºC as described13. Platelet 
activation/aggregation in the labelled PRP samples was performed as above with selected 
agonists and 1/6 volume of EDTA 0.05 M-formaldehyde 0.633 M was added to stop 
reactions. Then, cuvettes were centrifuged (12.000 x g, 2 min) to pellet platelets and 14C-
serotonin released into the supernatant was quantified by a liquid scintillation counter 
Wallac 1409 (Wallac Oy, AG&G Company, Turku, Finland), and reported as percentage of the 
total radioactivity incorporated, after correction for background13. 
 
Clot retraction 
Clot retraction assays were performed essentially as described14. Briefly, PRP samples 
adjusted with homologous PPP to a the final platelet count to 225 x 109L-1, were mixed in 
aggregation cuvettes with Tyrodes-Hepes buffer also containing small amount of red-blood 
cells. Clot formation was induced at RT with thrombin (1 UmL-1) and CaCl2 (2 mM), a sealed 
glass pipette was set at the center of the cuvette and clot retraction was monitored over 
time. 
 
Platelet flow cytometry 
Platelet expression of major platelet membrane glycoproteins (GP) (GPIa, GPIbα, GPIIb 
[αIIb], GPIIIa [β3]) was assessed by flow cytometry in citrated whole blood diluted 1:10 in 
saline buffer through a direct standard technique with appropriate labeled monoclonal 
antibodies in a FACScalibur platform (Becton Dickinson, San Jose, CA). For analysis of 
surface-expressed P-selectin (marker of α-granule release), and binding of fibrinogen 
(marker for activated αIIbβ3), diluted PRP (≈20 x  109L-1 platelets) was stimulated under static 
conditions (30 min at room temperature) with the desired agonist concentration in the 
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presence of both anti-CD62-PE antibody (BD Biosciences, Madrid, Spain) and fibrinogen-
Alexa488 (Thermo Fisher, Madrid, Spain). Samples were then run in FACSCalibur flow 
cytometer (Becton Dickinson) and the fluorescence of positively stained cells was analysed 
using CellQuest software.  
 
Platelet spreading 
Washed platelets were prepared as described15. Coverslips were coated overnight in 100µg 
mL-1 fibrinogen (Enzyme Research Lab, South Bend, IN) in sterile PBS at 4ºC.  The coverslips 
were blocked in denatured, sterile filtered 5mg/ml BSA (First Link UK Ltd, Birmingham, UK) in 
PBS.  Three hundred µl of washed platelets, adjusted to at 20 x 109 L-1, were added to each 
well and allowed to spread for 45 minutes at 37ºC.  Spread platelets were washed in PBS and 
fixed at room temperature in 4% PFA for 5 minutes.   Images were taken using a DM IRE2 
Leica inverted microscope, SP2 confocal system running Leica Confocal Software Version 
2.61 Build 1537. Platelet spreading assays were imaged using reflectance microscopy using 
the 488 nm line of an Argon-Ion laser 457-514 nM with an HCX Plan Apo Ibd.BL 63x NA 1.4, 
Olympus objective.  In order to calculate platelet spread area, 10 platelets from 10 different 
fields of view (FOV) (100 platelets per sample) were outlined using the ROI tool in ImageJ 
(1.48V).  The area measurements were then logged. Statistical significance was assessed by 
one-way ANOVA. 
 
Immunoblotting 
Total lysates from washed human platelets were separated by SDS–polyacrylamide gel 
electrophoresis on 4%–20% gradient gels and transferred to polyvinylidene fluoride 
membranes (Millipore). Standard Western blotting procedures were used. RAP1 (α-RAP1 
clone 121, Santa Cruz Biotechnology, Dallas, TX) and CalDAG-GEFI (polyclonal rabbit α-
RasGRP2, ThermoFisher Scientific, Waltham, MA) proteins were detected using IRDye 800-
conjugated goat anti-rabbit secondary antibodies (Li-Cor Biosystems, Lincoln, NE).  RASA3 
(polyclonal goat α-GAP1-InsP4BP (RASA3), Santa Cruz Biotechnology) and β-actin (α- β-actin 
clone AC-15, Sigma-Aldrich, St. Louis, MO) proteins were detected using IRDye 680–
conjugated donkey anti-goat and goat anti-mouse secondary antibodies (Li-Cor Biosystems), 
respectively, and visualized with the Odyssey Infrared Imaging System (Li-Cor Biosystems). 
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CalDAG-GEFI expression and purification 
Human CalDAG-GEFI and Rap1B proteins were overexpressed in E. coli and purified using a 
combination of immobilized metal affinity and size exclusion chromatography. Purified 
proteins were homogenous based on SDS-PAGE. Wild-type and mutant forms of CalDAG-
GEFI were expressed as truncations lacking 58 N-terminal residues predicted to be 
unstructured [CalDAG-GEFI (1-551)], while Rap1B was truncated at Cys181 and this residue 
mutated to serine [Rap1B (C181S)]. CalDAG-GEFI harboring S381F was not submitted to size 
exclusion chromatography due to protein instability.  
 
Nucleotide exchange activity assay  
Purified proteins were used to determine the GEF activity towards Rap1B of wild-type and 
mutant CalDAG-GEFI. Nucleotide exchange on Rap1B was monitored using Bodipy FL GDP, a 
fluorescent analog of GDP. The fluorescence of Bodipy FL GDP is quenched in solution and 
increases upon binding to Rap1B. To determine the GEF activity of CalDAG-GEFI mutants, 
purified Rap1B (1µM) was added to exchange buffer (20 mM Tris pH 7.5, 150 mM NaCl, 2 
mM MgCl2, 0.08% NP-40, 5% (v/v) glycerol, and 1 mM DTT) containing 1 µM GDP-BODIPY 
(Thermo Fisher), both in the absence or presence of 400 nM wild type or mutant CalDAG-
GEFI. Fluorescence data were collected on a Pherastar microplate reader (BMG LABTECH, 
Ortenberg, Germany) with λex = 485 nm, λem = 520 nm and 2 nm slits. 
   
Leukocyte studies  
Citrated whole blood samples containing 1 x 106 WBCs were resuspended in ice-cold 
hypotonic NaCl solution (0.2%) for 30 s, after which hypertonic (1.6%) NaCl solution (v:v) was 
added to restore isotonicity and cells were pelleted (5 min, 350 x g at 10ºC).  The lysis step 
was repeated once, and WBCs were resuspended in saline. To analyze surface glycoprotein 
expression, monoclonal antibodies for membrane glycoproteins CD11a and CD11b were 
used (Becton Dickinson). β2 integrin activation in stimulated neutrophils was analyzed by the 
ability of these cells to bind soluble fibrinogen or the conformation specific-antibody m24 
(Abcam, Cambridge, MA); to analyze granule release, cells were stained with and anti-CD11b 
Mac1 antibody (Becton Dickinson). Blood leukocytes were incubated with 60 µg mL-1 Alexa 
Fluor 488-fibrinogen (Thermo Fisher) and PerCP-anti CD45 (Becton Dickinson), PE-anti-Mac1 
and PerCP-anti CD45, or with 10 µg mL-1 m24. Saline, PMA, N-formyl-methionine-leucine-
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phenylalanine (fMLP), or manganese chloride (Mn2+) were added during this phase, for 30 
min at room temperature. Cells were washed, and either resuspended in saline, or tubes 
containing m24 were further incubated with a PerCP-anti mouse IgG1 (Santa Cruz 
Biotechnology) for 30 min, washed again, and resuspended in saline. 
To analyze β1 integrin expression, leukocytes were incubated with soluble VCAM-1/Fc 
chimera protein (R&D Systems, Minneapolis, MN), washed and stained with a FITC-
conjugated antibody to human IgG (Sigma-Aldrich, Madrid, Spain). Flow cytometry was 
conducted immediately after the final wash. 
A FACSCalibur flow cytometer (Becton Dickinson) and CellQuest and Paint-A-Gate softwares 
were used for analysis. Analysis of leukocyte subpopulations was performed on the basis of a 
CD45/side scatter (fibrinogen binding, CD11a and Mac-1 expression) or light scatter (m24 
and VCAM-1 binding) gating procedure. 
 
Statistical analysis  
Alls functional assays were performed with samples from three patients and three healthy 
controls. Due to the limited sample number, statistical comparisons could not be performed.    
 
 
Results  
 
Patient general information 
In this study we have characterized three patients from two unrelated families. The proband 
in Family 1 (P1-Family 1) is a 9-year-old Chinese child suffering from severe epistaxis 
requiring hospitalization and medical intervention, including nasal packing, tranexamic acid-
treatment and transfusion of red blood cells and platelets. In the second family the index-
case (P1-Family 2) is a 55-year-old Spanish woman, who has a lifelong history of 
spontaneous bruising, petechiae, epistaxis, gingival and gastrointestinal bleeding. Minor 
bleeding has been treated mainly with antifibrinolytic drugs. Menorrhagia required oral 
contraceptives and iron therapy.  Her two childbirths, dental extractions and minor surgical 
procedures have been successfully managed with prophylactic platelet transfusions. Her 46-
year-old brother, second proband in this family (P2-Family 2), also suffered from epistaxis, 
gingival and digestive bleeding in childhood requiring platelet transfusion. In adulthood, he 
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has experienced few bleeding episodes, but minor surgical procedures (colonoscopy and 
dental extractions) required the use of prophylactic desmopressin and antifibrinolytic drugs.  
In addition to their bleeding symptoms, these three patients displayed, on repeated testing, 
a normal platelet count and volume and mild anaemia (Table 1). Blood smears, leukocyte 
count and differential, markers of liver and kidney function, prothrombin time, activated 
partial thromboplastin time, fibrinogen and von Willebrand factor levels, were within normal 
ranges.  Our patients did not display overt immune defects, or susceptibility to bacterial 
infections other than P2-Family 2 suffering from ulcerative colitis.  
 
Platelet function studies 
A clinical suspicion of inherited platelet disorder was established in these patients due to the 
prolonged bleeding time, extended PFA-100® closure times (Table 1), and the severely 
reduced platelet aggregation in response to ADP and low dose collagen (Figure 1A). The 
expression level of major adhesive glycoproteins including GPIb/IX, GPIa, and GPVI, was 
normal (not shown).  Glanzmann’s thrombasthenia was ruled out for the three patients as (i) 
the surface expression of αIIbβ3 was not affected (not shown), and (ii) the platelet 
aggregation was normal, or minimally impaired, in response to high concentrations of 
protease-activated receptor 1 agonist peptide (PAR1p), collagen, arachidonic acid, or PMA 
(Figure 1A). Compared to controls, the lag time, i.e. the time required to reach 10% 
aggregation, was markedly increased in platelets from patients stimulated with 10 µg/mL 
collagen (0.93 ± 0.27 vs. 0.55 ± 0.07 min), 1.6 mM arachidonic acid (0.62 ± 0.12 vs. 0.24 ± 
0.01 min) or 10 µM ADP (0.43 ± 0.11 vs. 0.18 ± 0.09 min) (all mean ± SD; n = 3). No delay in 
the aggregation response to PMA or PAR1p was observed in the patient‘s platelets. 
Consistent with the delay in aggregation, platelets from the three patients exhibited 
markedly impaired fibrinogen binding upon stimulation with most agonists (ADP, PAR1p, 
PAR4p, CRP) (Figure 1B). In contrast, the patients’ platelets showed only minor defects in 
agonist-induced α- or δ- granule secretion (Supplemental Figures 1A and 1B), clot retraction 
(Supplemental Figure 2), and spreading on fibrinogen (Supplemental Figure 3).   
 
Identification of deleterious mutations in RASGP2.   
Aiming to identify the molecular defects responsible for the bleeding phenotype in these 
patients, DNA from the Chinese boy and the Spanish siblings was analyzed by a novel NGS 
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panel covering 71-genes known or suspected to play a relevant role in IPDs (Supplemental  
Table 1) and whole exome sequencing (WES), respectively. As shown in Figure 2A, these 
molecular analyses identified novel homozygous changes in the RASGRP2 gene in the index 
cases: i) a nonsynonymous change c.1142C>T (p.Ser381Phe) in exon 10 in Family 1; ii) a 
nonsense change c.337C>T (p.Arg113X) in exon 5 in Family 2.  Sanger sequencing confirmed 
the presence of these mutations in the probands and their inheritance from the 
consanguineous parents (Figure 3). CalDAG-GEFI, the RASGRP2 encoded protein, contains an 
N-terminal catalytic region, comprising a Ras exchange motif (REM) and a CDC25 domain 
that provides GEF activity, and a C-terminal regulatory region with two Ca2+ binding EF hand 
domains and a C1-like domain16 (Figure 2B). The nonsense c.337C>T (p.Arg113X) variant is 
expected to truncate CalDAG-GEFI synthesis at the level of the REM motif, while the  
p.Ser381Phe substitution is located at the C-terminal end of the CDC25 catalytic domain, and 
it is predicted by PolyPhen (http://genetics.bwh.harvard.edu/pph2/) to be “probably 
damaging” with a score of 1.0. The p.Ser381Phe variant is reported with an allelic frequency 
of 8.47 x 10-6 in the Exome Aggregation Consortium database (ExAC) 
(http://exac.broadinstitute.org), and it is unreported in the 1000 genomes project database 
(http://browser.1000genomes.org). The p.Arg113X is reported as somatic mutation in the 
COSMIC project (http://cancer.sanger.ac.uk)(All database accessed on 05/10/2016).   
 
Novel RASGRP2 mutations impair CalDAG-GEFI expression and function. 
Immunoblotting analysis demonstrated that CalDAG-GEFI expression was markedly reduced 
in platelets from index cases homozygous for p.Ser381Phe or p.Arg113X and moderately 
decreased in platelets from available heterozygous relatives. In contrast, expression of Rap1 
itself and Rasa3, a main Rap1-GAP in platelets7, was comparable in platelets from affected 
individuals and healthy volunteers (Figure 4). To evaluate whether the Ser381Phe 
substitution also impairs the GEF activity of CalDAG-GEFI, we purified the wild-type and 
mutant protein and subjected them to a novel, fluorescence-based assay to monitor 
nucleotide exchange on purified Rap1B. In this assay, nucleotide exchange on Rap1B is 
monitored with the help of Bodipy FL GDP, a fluorescent analog of GDP that is quenched in 
solution but shows increased fluorescence upon binding to Rap1B. As shown in Figure 5A, 
loading of Rap1 with Bodipy FL GDP occurred very slowly, unless it was catalyzed by the 
addition of CalDAG-GEFI. Interestingly, large amounts of CalDAG-GEFI (Ser381Phe), but not 
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CalDAG-GEFI (wild-type), precipitated during the purification process, suggesting altered 
stability of the patient protein. Non-aggregated CalDAG-GEFI (Ser381Phe) protein showed 
strongly reduced GEF activity when added to Rap1B at the same concentration as CalDAG-
GEFI (wild-type). The reduction in the catalytic activity was similar to that observed with 
purified CalDAG-GEFI bearing a Gly248Trp substitution, the only other known CalDAG-GEFI 
mutation in humans5 (Figure 5A). Noteworthy, while Gly248 is positioned in the interface 
between the CDC25 domain and Rap15, Ser381 localizes to an adjacent region (Figure 5B). 
Based on structural modelling, we propose that the p.Ser381Phe substitution clashes with 
Leu263, Ser305 and Leu309 and thus causes a conformational change in CalDAG-GEFI which 
affects both protein stability and nucleotide exchange activity.  
 
Neutrophil function studies.  
Studies in mutant mice identified a role for CalDAG-GEFI in neutrophil integrin affinity 
modulation and adhesion10. We thus investigated whether neutrophil function was also 
affected in homozygous carriers of the CalDAG-GEFI S381F and R113X mutations (Figure 6). 
Compared to controls, neutrophils from homozygous patients showed normal β2 integrin 
and reduced β1 integrin expression (Supplemental Table 2). β2 integrin activation was 
impaired in stimulated neutrophils from homozygous RASGRP2 patients (Figure 6A and 6B).  
Thus, when activated with fMLP, which causes inside-out activation, or by agents such as 
Mn2 that increase integrin affinity by direct and indirect (signaling) effects17, patient 
neutrophils displayed a markedly impaired ability to bind fibrinogen (Figure 6A). 
Consistently, the binding of an antibody detecting the active conformation of LFA-1 (m24) 
was also reduced in Mn2+ activated patient neutrophils when compared to controls (Figure 
6B). In contrast, granule secretion was only minimally affected in neutrophils from 
homozygous patients (Figure 6C). 
 
 
Discussion  
We here report two families with a bleeding diathesis and platelet dysfunction, resulting 
from novel mutations in RASGRP2 that affect the expression and/or function of CalDAG-
GEFI. This defect causes a markedly impaired aggregation response to low concentrations of 
certain agonists, most prominently ADP and collagen, and a delay in aggregation, even when 
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stimulated with high concentrations of most agonists. Our findings, together with an earlier 
study5, strengthen the molecular heterogeneity of RASGRP2 as a cause of inherited platelet 
disorder associated with impaired αIIbβ3 integrin activation. 
In addition to the defect in platelet αIIbβ3 activation, we observed alterations in the 
expression or function of β1and β2 integrins in neutrophils. Neutrophils from homozygous 
patients exhibited reduced surface expression of β1 integrins, a finding that is in accordance 
with results reported in Rasgrp2 knock-out mice10. Furthermore, patient neutrophils showed 
defects in agonist-induced inside-out activation of β2 integrins, confirming that CalDAG-GEFI 
is critical for the affinity modulation various integrin subfamilies10,18.  The fact that fibrinogen 
binding to β2 integrins was also impaired in patient neutrophils stimulated with Mn2+ 
supports the concept that Rap1 is involved in both inside-out and out-side-in signaling, as 
previously suggested19. Interestingly, recent studies by Canault et al. did not reveal any 
defects in integrin-mediated adhesion of neutrophils from patients with a loss-of-function 
mutation in RASGRP2 5. As discussed by the authors, the absence of an adhesion defect in 
CalDAG-GEFI (pG248W) neutrophils may be explained by the fact these cells express normal 
level of mutant protein, i.e. that this mutation may spare structural domains that facilitate 
leukocyte adhesive functions. Further studies will be required to test this hypothesis.  
Mice lacking CalDAG-GEFI are characterized by a very strong protection from experimental 
thrombosis, a moderate deficit in hemostasis, and a very mild immunodeficiency6,8-10. 
Including the patients described in this paper, there are now a total of six patients (4 males, 
2 females) with three distinct mutations in RASGRP2. All of the patients are characterized by 
impaired platelet aggregation to select agonists and markedly prolonged bleeding times. 
They all exhibit lifelong bleeding complications, including spontaneous bruising, petechiae, 
epistaxis, gingival and gastrointestinal bleeding. Interestingly, these bleeding complications 
seem to be less severe in adults, such as the 46-year old proband in family 2 who has 
experienced few bleeding episodes during adulthood. None of the reported patients showed 
clinical signs of immunodeficiency. Due to the small number of patients, it is not possible to 
evaluate if mutations in RASGRP2 also lead to protection in humans from thrombotic 
complications associated with cardiovascular disease. This would seem likely, however, given 
the critical role of CalDAG-GEFI in platelet adhesion at high shear stress conditions and the 
fact that the Rap1 signaling response in human platelets is very similar to that in murine 
platelets.  
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In summary, we here report two novel mutations in RASGRP2 that lead to partially impaired 
integrin activation in platelets and neutrophils. Homozygous patients display a life-long, 
bleeding tendency, but they do not show signs of immunodeficiency. Only with the 
availability of increased numbers of patients, will it become clear whether they are 
protected against thrombotic disease.   
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Legend to Figures 
Figure 1.  Platelet aggregation and integrin activation is markedly impaired in index cases 
with lifelong bleeding diathesis from two unrelated families. 
A) Platelet aggregation in response to the indicated platelet agonists was evaluated in 
unadjusted platelet-rich plasma from index cases (P) and a healthy and unrelated control 
(C).  B) Platelets from index cases and healthy and unrelated controls (controls) (combined 
data from three subjects), were stimulated under static conditions (30 min at RT) with 
agonist (5 and 25 µM ADP [ADP-5 & ADP-25], 25 µM PAR1 peptide [PAR1p], 250 µM PAR4 
peptide [PAR4p], 2 and 10 µg mL-1 collagen-related-peptide [CRP-2 & CRP-10], 2 µg mL-1 
convulxin [Cvx], and 100 nM Phorbol 12-myristate 13-acetate [PMA]) in the presence of 
fibrinogen-Alexa 488. The samples were evaluated by flow cytometry and the median 
fluorescence intensity [MFI]) for Fibrinogen-A488 binding is shown. 
 
Figure 2: Localization of the novel c.1142C>T (p.S381F) and c.337C>T (p.R113X) mutations 
within the RASGRP2 sequence and the encoded protein CalDAG-GEFI. 
DNA from index cases was analysed by next generation sequencing or whole exome 
sequencing and novel mutations in RASGRP2 were identified. A) Localization of the novel 
c.1142C>T (p.S381F; Family 1) and c.337C>T (p.R113X; Family 2) mutations within the 
RASGRP2 sequence.  B) Schematic representation for CalDAG-GEFI showing the different 
domains: Ras exchanger motif (REM), catalytic domain (Cdc25), calcium-binding EF hands 
(EF) and C1-like domain (unknown function). The positions of the recently reported G248W 
mutation5 and the novel p.R113X and p.S381F mutations within the REM and Cdc25 
domains are shown. 
 
Figure 3: Family pedigrees and bleeding scores in two unrelated families carrying novel 
mutations S381F and R113X in CalDAG-GEFI. 
The index cases in each family are indicated with black arrows.  Bleeding in patients and 
available family members was evaluated and scored (BS) using the ISTH Bleeding 
Assessment tool20. Filled and semi-filled black symbols indicate homozygosis and 
heterozygosis for the correspondent mutation in RASGRP2. Other family members (white 
symbols) were not-available for study.  
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Figure 4.  Novel mutations R113X and S381F severely affect the expression of CalDAG-
GEFI. 
Immunoblot analysis for CalDAG-GEFI (CDGI), Rasa3, Rap1 and β-actin in platelet lysates 
from carriers of the indicated mutations in CalDAG-GEFI. Left: p.S381F (P1 homozygous; P2, 
P3, P4 heterozygous); Right: p.S381F mutation (P1 and P2 homozygous; P3 heterozygous). 
Protein expression in lysates from healthy and unrelated controls (C) analyzed in parallel is 
also shown.  
 
Figure 5. The S381F substitution alters CalDAG-GEFI structure and markedly impairs its 
nucleotide exchange activity. 
A) Bodipy fluorescence-based assay to monitor nucleotide exchange on purified Rap1B. 
Black arrow indicates where wild-type (green) or S381F (red) or G248W (blue) CalDAG-GEFI 
was added. The increase in fluorescence intensity, a measure of nucleotide exchange, over 
time is shown. B) A structural model of the S381F substitution using the mutagenesis 
feature in pymol. This model was built based on the crystal structure of CalDAG-GEFII21 and 
represents phenylalanine substituted for serine at position 430, the homologous position of 
serine 381 of CalDAG-GEFI. Based on this model, there are 3 residues that clash with the 
phenylalanine substitution at S430: Leucine 263, Serine 305, and Leucine 309.   
 
Figure 6: Impaired integrin activation in leukocytes from homozygous carriers of the 
CalDAG-GEFI S381F and R113X mutations.  
A,B) β2 integrin activation. Neutrophils were kept resting or stimulated with the indicated 
agonists in the presence of Alexa Fluor 488-fibrinogen (A) or m24 antibody (B) to determine 
the activation state of αMβ2 and αLβ2, respectively. C) Granule secretion. Neutrophils were 
kept resting or stimulated with fMLP (1 mM) or PMA (100 nM) in the presence of a PE-
labeled antibody to CD11b (Mac-1). Results are expressed as the fold increase in median 
fluorescence intensity in stimulated vs. unstimulated cells. Values are mean ± SEM from 
data obtained in the three homozygous patients (black bars) and three healthy controls 
(gray bars).   
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Table 1.  Blood parameters and clinical bleeding symptoms in homozygous carriers of the 
novel mutations S381F and R113X in CalDAG-GEFI  
 
P1-S381F P1-R113X P2-R113X 
WBC (x109/L) 7.2 ± 1.2 8.0 ± 0.2 7.9 ± 1.1 
RBC (x1012/L) 4.8 ± 0.4 3.9 ± 0.1 4.6 ± 0.1 
Hb (g/dL) 11.4 ± 1.9 10.9 ± 0.6 12.5 ± 0.5 
Ht (%) 37.7 ± 8.9 32.9 ± 2.5 38.5 ± 0.5 
Platelets (x109/L) 351.5 ± 84.1 182.0 ± 9.9 246.0 ±22.6 
MPV  (fL) 8.5 ± 0.9 10.1 ± 2.2 10.0 ± 3.0 
PFA-100 CT (s) 
Collagen/Epinephrine 
Collagen/ADP 
>300 
>300 
>300 
244 
>300 
275 
Location of bleeding and score 
Epistaxis 4 4 4 
Cutaneous symptoms 1 2 - 
Minor wounds 1 - 2 
Oral cavity bleeding 1 - - 
Gastrointestinal 
bleeding  
4 1 
Final Bleeding score 7 10 7 
Values are mean ± SD from two different complete blood counts separated at least two years.   
Abbreviations: WBC: white blood cells; RBC: red blood cells; Hb: Hemoglobin; Ht: Hematocrit; MPV: 
Mean platelet volume; CT: closure time. The Table reflects the clinical significant bleeding for each 
symptom, grading the bleeding severity from 0 (absence of symptoms) to 4. The final bleeding score 
was generated by summing the severity of all bleeding symptoms reported by the patient21 
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